A new set of draft amendments applied to the Pharmaceutical Affairs Law will cause the domestic pharmaceutical industry to lose about NT$4 billion (US$117.3 million) in its annual production value during a five-year period and an increase of NT$3.5 billion (US$102.7 million) in medical expenses under the national health insurance programme.